

Learning 2 Sleep completes the acquisition of the intestinal flora analysis company Symbio Me AB

Learning 2 Sleep L2S AB (publ) ("L2S") has completed the acquisition of Symbio Me AB ("Symbio Me" or "the Company") - a digital intestinal flora analysis company - which was announced on May 9, 2022. The purchase price of SEK 10 million has been paid through that the board of L2S has decided on the issue and allotment of 1,694,915 shares in L2S, which are issued at a price of approximately SEK 5.90 per share.

L2S has completed the acquisition of Symbio Me, which was announced on May 9, 2022. The company offers research-based intestinal flora analysis directly to consumers. The purchase price of SEK 10 million has been paid by the Board of L2S having decided on the issue and allotment of 1,694,915 shares in L2S to the sellers of the Company, who have paid full payment for the subscribed and allotted shares in the form of the shares in the Company. In connection with the issue, L2S's share capital will be increased by approximately SEK 101,695 to approximately SEK 827,218 and the number of shares in L2S will increase from 12,092,058 to 13,786,973 shares in connection with the issue.

Contacts

For more information please contact:

Micael Gustafsson, CEO Mobile: +4673 699 36 01

mail: micael@learningtosleep.se

About Us

Learning to Sleep is a digital care provider specializing in the treatment of chronic sleep disorders. The treatment is a combination of a structured treatment program in a mobile application and weekly digital meetings with a psychologist. The company's treatment is based on the latest research in the field and is very successful - over 90 percent of the patients treated receive improved sleep. Sweden is the company's main market and the treatment is reimbuserd by public health care.

For more information see www.learningtosleep.co.uk
The company's Certified Adviser is Eminova Fondkomission AB | +468 684 211 10 |
adviser@eminova.se



A L	۱.	_ _			
Αt	a	cn	ım	en	ITS

Learning 2 Sleep completes the acquisition of the intestinal flora analysis company Symbio Me AB